NCT02947347 2026-03-17
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC.
Phase 3 Completed
Clinical Trials
56 trialsNCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT01476787 2025-05-14
RELEVANCE
Celgene
Phase 3 Completed
NCT04745832 2024-11-04
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
Phase 3 Terminated
NCT03078855 2024-09-04
ILyAD
University of Rochester
Phase 3 Completed
NCT04934670 2024-08-27
2002
Xenikos
Phase 3 Terminated
NCT03721172 2024-05-29
ADVANCE
Amgen
Phase 3 Completed
NCT02204982 2023-09-28
DYNAMO + R
SecuraBio
Phase 3 Terminated
NCT02536300 2023-08-14
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Gilead Sciences
Phase 3 Terminated
NCT01510184 2021-12-16
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01597778 2021-12-01
Double Cord Versus Haploidentical (BMT CTN 1101)
Medical College of Wisconsin
Phase 3 Completed
NCT01321541 2021-11-19
PIX-R
CTI BioPharma
Phase 3 Completed
NCT01662102 2021-10-04
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03993288 2021-07-12
Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.
Sandoz
Phase 3 Completed
NCT02093663 2021-06-09
PACE
Takeda
Phase 3 Completed
NCT01419665 2021-05-14
ASSIST_FL
Sandoz
Phase 3 Completed
NCT02260804 2021-04-08
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Celltrion
Phase 3 Completed
NCT00004031 2021-02-02
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT00577993 2020-11-16
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Phase 3 Completed
NCT02809053 2020-10-08
RAMO-2
Archigen Biotech Limited
Phase 3 Completed
NCT01077518 2020-03-27
A+B
Novartis
Phase 3 Terminated
NCT02210689 2020-01-28
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
Actavis Inc.
Phase 3 Completed
NCT01059630 2020-01-13
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Genentech, Inc.
Phase 3 Completed
NCT01805791 2020-01-02
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
Hutchmed
Phase 3 Terminated
NCT01527357 2019-12-18
FINISH-3
Mallinckrodt
Phase 3 Completed
NCT03357471 2019-10-25
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
UCB Pharma
Phase 3 Completed
NCT02213263 2019-06-20
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Pfizer
Phase 3 Completed
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated
NCT00562965 2018-01-09
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Pfizer
Phase 3 Terminated
NCT00348140 2017-09-05
REFLECT-3
GlaxoSmithKline
Phase 3 Completed
NCT01163253 2017-06-26
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Terminated
NCT00428090 2017-05-19
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
GlaxoSmithKline
Phase 3 Completed
NCT01313221 2017-03-15
REFINE
Amgen
Phase 3 Completed
NCT00755040 2017-03-07
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Vanderbilt-Ingram Cancer Center
Phase 3 Completed
NCT00719563 2017-02-09
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01426373 2016-01-14
Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
Kythera Biopharmaceuticals
Phase 3 Completed
NCT02569996 2015-12-10
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
Hoffmann-La Roche
Phase 3 Completed
NCT01519089 2015-08-13
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
Phase 3 Completed
NCT02007434 2015-07-28
Patient Experience Study of Deoxycholic Acid Injection
Kythera Biopharmaceuticals
Phase 3 Completed
NCT01305577 2015-07-14
Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Kythera Biopharmaceuticals
Phase 3 Completed
NCT01542034 2015-06-15
REFINE-1
Kythera Biopharmaceuticals
Phase 3 Completed
NCT01546142 2015-06-15
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Kythera Biopharmaceuticals
Phase 3 Completed
NCT01294644 2015-06-12
Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Kythera Biopharmaceuticals
Phase 3 Completed